Andrew Kuykendall, MD, discusses the background, methods, and design of a phase 2 study which evaluated fedratinib.

Addressing barriers in acute myeloid leukaemia care in India to improve outcomes and survival rates for patients.

A research team from Osaka University investigates the impact of antioxidant enzymes on specific cell types and their role in ...

It can be hypothesized that in myeloid diseases, such as MDS, defects in cells that play a crucial role in orchestrating immune responses are highly relevant in the pathophysiology of the disease.

Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...

Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in ...

commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com. This press release contains forward-looking statements.

Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid leukemia (AML), which is associated with an increased risk of relapse. The ...

commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com. Forward-Looking Statements This press release contains ...